I-Mounjaro(i-Tirzepatide) iyisidakamizwa sokunciphisa umzimba kanye nokunakekelwa okuqukethe into esebenzayo i-tirzepatide. I-Tirzepatide iyi-agonist esebenza isikhathi eside ye-GIP ekabili kanye ne-GLP-1. Womabili ama-receptors atholakala kumaseli e-pancreatic alpha kanye ne-beta endocrine, inhliziyo, imithambo yegazi, amangqamuzana omzimba omzimba (ama-leukocyte), amathumbu nezinso. Ama-receptors e-GIP nawo atholakala kuma-adipocyte.
Ngaphezu kwalokho, womabili ama-receptors e-GIP kanye ne-GLP-1 avezwa ezindaweni zobuchopho ezibalulekile ekulawuleni ukudla. I-Tirzepatide ikhetha kakhulu kuma-receptors e-GIP kanye ne-GLP-1. I-Tirzepatide inobudlelwane obuphezulu kuzo zombili i-GIP kanye ne-GLP-1 receptors. Umsebenzi we-tirzepatide kuma-receptors e-GIP ufana nalowo we-hormone ye-GIP yemvelo. Umsebenzi we-tirzepatide kuma-GLP-1 receptors uphansi kunalowo we-hormone yemvelo ye-GLP-1.
I-Mounjaro(Tirzepatide) isebenza ngokwenza ama-receptors ebuchosheni alawula ukudla, akwenze uzizwe ugcwele, ungalambi, futhi mancane amathuba okuba ufise ukudla. Lokhu kuzokusiza ukuthi udle kancane futhi ulahlekelwe isisindo.
I-Mounjaro kufanele isetshenziswe nohlelo lokudla olunekhalori encishisiwe kanye nokuzivocavoca umzimba okwandisiwe.
Imibandela Yokufaka
I-Mounjaro(Tirzepatide) ikhonjiswe ekulawuleni isisindo, okuhlanganisa ukuncipha nokugcinwa kwesisindo, njengesengezo ekudleni okunekhalori encishisiwe kanye nokwanda kokuzivocavoca umzimba kubantu abadala abanenkomba yesisindo somzimba sokuqala (BMI) ye:
≥ 30 kg/m2 (okukhuluphala), noma
≥ 27 kg/m2 kuya ku-<30 kg/m2 (okukhuluphele) okungenani okukodwa okuhambisana nesisindo okuhambisana nesisindo esifana ne-dysglycemia (i-prediabetes noma uhlobo 2 sikashukela), umfutho wegazi ophakeme, i-dyslipidemia, noma i-apnea evimbelayo yokulala Imvume yokwelashwa nokunamathela ekudleni okwanele
Iminyaka engu-18-75
Uma isiguli sihluleka ukulahlekelwa okungenani u-5% wesisindo somzimba saso sokuqala ngemva kwezinyanga eziyisi-6 zokwelashwa, kudingeka kwenziwe isinqumo sokuthi sizoqhubeka nokwelashwa, kucatshangelwa inzuzo/iphrofayili yengozi yesiguli ngasinye.
Dosing schedule
Umthamo wokuqala we-tirzepatide ngu-2.5 mg kanye ngesonto. Ngemuva kwamaviki ama-4, umthamo kufanele unyuswe ube ngu-5 mg kanye ngesonto. Uma kudingeka, umthamo unganyuswa ngo-2.5 mg okungenani amaviki angu-4 ngaphezu komthamo wamanje.
Imithamo yesondlo enconyiwe ingu-5, 10, no-15 mg.
Umthamo omkhulu ngu-15 mg kanye ngesonto.
Dosing indlela
I-Mounjaro(Tirzepatide) ingase inikezwe kanye ngesonto nganoma yisiphi isikhathi sosuku, ngokudla noma ngaphandle kokudla.
Kufanele ijovwe ngaphansi kwesikhumba esiswini, ethangeni, noma engalweni engenhla. Indawo yomjovo ingase ishintshwe. Akufanele ijovwe nge-intramuscularly noma nge-intramuscularly.
Uma kudingeka, usuku lokudosa lwamasonto onke lungashintshwa inqobo nje uma isikhathi esiphakathi kwemithamo siyizinsuku ezi-3 okungenani (> amahora angama-72). Uma usuku olusha lokudosa selukhethiwe, umthamo kufanele uqhubeke kanye ngesonto.
Iziguli kufanele zelulekwe ukuthi zifunde imiyalelo yokusetshenziswa ephaketheni ngokucophelela ngaphambi kokuthatha umuthi.
Isikhathi sokuthumela: Feb-15-2025